Homologous Recombination Deficiency Solution

Highly accurate HRD testing goes beyond detecting HRR mutations. Open new doors in cancer testing by identifying the relevant variants and genomic integrity using the cost-effective and easily implementable SOPHiA HRD Solution.
pink dots icon
The SOPHiA HRD Solution offers cost-effective, reliable and timely in-house results to empower better clinical research decisions. Our convenient decentralized approach helps you keep ownership of data and save time while also offering comprehensive genomic insights without compromising data quality through the SOPHiA DDM™ platform. This application provides a unique approach for molecular cancer testing by combining identification of HRD-causing mutations with the measurement of HRD-induced genomic instability.

What is HRD and why is it important?

Homologous recombination deficiency (HRD) is caused by cells’ inability to repair double-stranded DNA breaks with homologous recombination repair (HRR), causing mutations that lead to development of certain cancers. Germline and somatic molecular testing allow the detection of HRR mutations that cause HRD and the accumulated genomic damage that result from them. However, over the last decade, HRD has become the new gold standard to help inform cancer care strategies.

Current challenges with HRD detection offerings

  • Data not owned by the lab
  • Costly
  • Weak solution support

Benefits of the SOPHiA HRD Solution

Laboratories can conduct HRD testing in a decentralized approach, allowing them to retain and own all data
The SOPHiA DDM™ platform benefits: continuously learning proprietary algorithms, SOPHiA GENETICS Community, OncoPortal™
Identifying mutations in 28 HRR genes and measuring genomic integrity in a single assay
Strong solution support
Cost-effective
pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.